ATH 1020
Alternative Names: ATH-1020Latest Information Update: 07 Apr 2023
At a glance
- Originator Athira Pharma
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action Hepatocyte growth factor stimulants; Proto-oncogene protein c-met stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neurological disorders; Psychiatric disorders
- Preclinical Neuropathic pain
Most Recent Events
- 05 Jan 2023 Adverse events data from a phase I pharmacokinetics trial released by Athira Pharma
- 31 Dec 2022 Athira Pharma completes phase I trial in Psychiatric disorders and Neurological disorders (In adults, In the elderly, In volunteers) in USA (PO) prior to December 2022 (NCT05169671)
- 16 Nov 2022 Preclinical trials in Neuropathic pain in USA prior to 16 November 2022 (PO)